Study: Rushing FDA approvals might compromise drug safety

Harvard University researchers found drugs the FDA cleared shortly before its deadline are more prone to safety problems than those approved with time to spare. The FDA said it does not grant approval unless it is ready. It "has the option of denying approval altogether if there is any question about safety," said Janet Woodcock, head of the agency's Center for Drug Evaluation and Research.

View Full Article in:

Wall Street Journal (free content), The · Washington Post (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA